TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00868790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
Study: NCT04601792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tested drug minus heat-clearing herbs
Description: It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tested drug minus heat-clearing herbs
Description: It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
Study: NCT02853682

Intervention type: BIOLOGICAL
Intervention: plasma
Description: assesment of glycocalyx protein

Intervention type: BIOLOGICAL
Intervention: plasma
Description: assesment of glycocalyx protein
Study: NCT02045550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prospan Syrup
Description: 2.5 ml twice daily for 4 weeks
Study: NCT01042886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PILI 'Ohana Lifestyle Program
Description: 9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Maintenance Program
Description: 9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
Study: NCT02406898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: morcellator uterine system (MH)Karl Storz, Tuttligen- Germany

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: morcellator uterine system (MH)Karl Storz, Tuttligen- Germany
Study: NCT04189250

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments
Description: The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.
Study: NCT00868790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
Study: NCT04189250

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Automatized carbonmonoxide rebreathing machine - OpCO Detalo instruments
Description: The automatized protocol (aCO) will be conducted with automated system OpCO of Detalo instruments. The intended use of the OpCO Detalo instrument is to quantify hemoglobin mass in human. The principle behind the machine is the widely used CO rebreathing technique. The machine applies automatically the desired CO dose to the patient to determine hemoglobin mass. The Detalo Instruments OpCO is certified conform to the following CE norms: Electromagentic compabilitiy: DIN EN 60601-1-2 and electrical Safety test: LVD 2014/35/EU.
Study: NCT01719731

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: This group will receive the psychoeducation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Education
Description: This group will not receive the psychoeducation
Study: NCT00282347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was provided as a sterile solution for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided as a sterile solution for injection.
Study: NCT00550537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/m2 given through a vein for every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC = 6 given through a vein on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 150 mg taken by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200 mg/m2 given through a vein on day 1 of each cycle.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Blood and tissue collection.
Study: NCT00282347

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate mofetil
Study: NCT00550537

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Blood and tissue collection.
Study: NCT00868790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
Study: NCT00564993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamin
Description: 10\&20 µg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamin
Description: 10\&20 µg/kg/min
Study: NCT01849757

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: prime crystalloid
Description: used for priming the CPB circuit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human Albumin
Description: Used as a constituent for priming the CPB circuit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voluven
Description: Used as a constituent for priming the CPB circuit
Study: NCT01834404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine-Topiramate ER
Description: The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills matched the study drug in appearance for the 2 dose levels.
Study: NCT03827161

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT00282347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study: NCT02243423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SUPINE
Description: Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.~A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TILT
Description: Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.~A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline.
Study: NCT04176042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Track 1
Description: Intervention + Follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Track 2
Description: Wait list + Intervention
Study: NCT02996032

Intervention type: OTHER
Intervention: Vascular and Pulmonary Ultrasound
Study: NCT03337789

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polygonatum sibiricum
Description: Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks
Study: NCT00859027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 35 mg/week by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo risedronate oral tablet
Description: One tablet by mouth every week as directed
Study: NCT01128023

Intervention type: OTHER
Intervention: Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT
Description: Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.

Intervention type: OTHER
Intervention: Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT
Description: Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
Study: NCT02386670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS + CR
Description: First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS + sham CR
Description: First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely).
Study: NCT03467100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN901
Description: Capsule filled with XEN901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert Ingredients Oral Product
Description: Placebo capsule
Study: NCT04316975

Intervention type: OTHER
Group type: OTHER
Intervention: Study Driven Procurement of Biopsies
Description: Four research biopsies collected at the midpoint of current BE or IMC at Baseline and after reaching CEIM. Biopsies will be used to calculate ML scores both pre and post EET.
Study: NCT02524834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exclusion of thoracoabdominal lesion
Description: Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Device Implant
Description: Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
Study: NCT01449942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNAzyme targeting EBV-LMP1 (DZ1)
Description: DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DNAzyme targeting EBV-LMP1 (DZ1)
Description: DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.
Study: NCT01396369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Birth control
Description: In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birth control plus Brevail
Description: In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
Study: NCT02618369

Intervention type: DEVICE
Group type: OTHER
Intervention: MR-Guided High Intensity Focused Ultrasound
Description: Target treatment of bone lesion using High Intensity Focused Ultrasound
Study: NCT02866864

Intervention type: OTHER
Intervention: Animal allergy +
Description: Allergic symptom occurs when subject contact animal
Study: NCT01449942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.
Study: NCT03337828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol-free beer with regular composition
Description: Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-free beer with modified composition
Description: Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
Study: NCT04113369

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: 30 minutes of conventional antalgic TENS to non-paretic forearm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: 40 minutes of lower limb training and 20 minutes of upper extremity training for stroke

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional rehabilitation
Description: 40 minutes of lower limb training and 20 minutes of upper extremity training for stroke

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: 20 minutes of EMS to non-paretic forearm with 5 minutes of pre and post warm-up
Study: NCT05206656

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eribulin Mesylate
Description: Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.
Study: NCT02058745

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAU+ (Enhanced Care as Usual)
Description: CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAU+ (Enhanced Care as Usual)
Description: CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAU+ (Enhanced Care as Usual)
Description: CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson.
Study: NCT02866864

Intervention type: OTHER
Intervention: Animal allergy -
Description: Allergic symptom does not occur when subject contact animal
Study: NCT02514759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Teen Outreach Program
Description: Students received the Teen Outreach Program as described previously.
Study: NCT00550537

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: Blood and tissue collection.